Pfizer launches novel programs to put important support services at the fingertips of cancer patients

PfizerPfizer today unveils enhanced offerings to help patients manage their life with cancer. Pfizer Oncology Together is a first-of-its-kind program for patients taking Pfizer Oncology medicines that offers dedicated social workers called 'Care Champions' to help navigate the complexities that accompany treatment, such as identifying resources to help find emotional support, and workplace transition, transportation and financial assistance. For cancer patients taking a Pfizer Oncology medicine, please visit www.PfizerOncologyTogether.com.

Pfizer is also proud to launch This is Living with Cancer™, a program that provides tools and resources to support those who have been affected by cancer, including a mobile app, LivingWith, designed to help manage some of the daily challenges faced by people living with cancer. For more information about the program and to find out more about LivingWith, visit www.ThisIsLivingWithCancer.com.

"Today, more than 15 million people in the United States are living with cancer and that number is expected to grow as emerging science and better therapies are likely to increase the number of patients living with cancer as we strive for a cure," said Liz Barrett, Global President, Pfizer Oncology. "Navigating life with cancer poses many challenges for patients and their families and friends, and we hope these unique programs can help their journey."

"Cancer patients can feel isolated and unsure about how to navigate care and approach day-to-day life," said Myra Biblowit, President & CEO, Breast Cancer Research Foundation. "Pfizer's new programming that goes beyond treatment is critical in helping patients and their care networks deal with the challenges associated with living with cancer."

About Pfizer Oncology Together
Pfizer Oncology Together is a portfolio-wide program for patient access solutions and support in the U.S. As part of the program, patients receiving Pfizer Oncology medicines will have access to a team of social workers who will be able to provide support beyond the traditional access and reimbursement services by connecting them with a wide variety of patient education resources and outreach programs. The support programs include identifying independent third party resources that provide emotional support, lodging, transportation, workplace transition support for patients balancing their jobs and treatment, and connecting patients and their families to local advocacy groups. This service will provide patients and caregivers with a dedicated representative over the course of their treatment.

About This is Living with CancerTM and LivingWith
LivingWith provides patients and caregivers with a tool to organize certain important information in one place, including:

  • Build a network of support from friends and family to get help with daily tasks
  • Record and remember important information from doctor visits
  • Track mood, pain and connect with wearables
  • Get organized and store key documents
  • Receive information about local events and nutrition articles
  • LivingWith is available at no charge and can be downloaded at the Apple App store or Google Play.

About Pfizer Oncology
Pfizer Oncology is committed to pursuing innovative treatments that have a meaningful impact on those living with cancer. As a leader in oncology speeding cures and accessible breakthrough medicines to patients, Pfizer Oncology is helping to redefine life with cancer. Our strong pipeline of biologics, small molecules and immunotherapies, one of the most robust in the industry, is studied with precise focus on identifying and translating the best scientific breakthroughs into clinical application for patients across a wide range of cancers. By working collaboratively with academic institutions, individual researchers, cooperative research groups, governments and licensing partners, Pfizer Oncology strives to cure or control cancer with its breakthrough medicines. Because Pfizer Oncology knows that success in oncology is not measured solely by the medicines you manufacture, but rather by the meaningful partnerships you make to have a more positive impact on people's lives.

Pfizer Inc.: Working together for a healthier worldTM
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

Most Popular Now

Positive Phase 1 data from mRNA-based individualiz…

BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability o...

FDA approves RIABNI™ (rituximab-arrx), a biosimila…

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with ...

Pfizer to invest $120 million to produce COVID-19 …

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Mic...

Proteomic study of 2,002 tumors identifies 11 pan-…

A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowled...

A new technology offers treatment for HIV infectio…

A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The s...

Sanoff offers perspective on a promising rectal ca…

UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on ...

Boehringer Ingelheim signs option to acquire Truti…

Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. (the "Transaction"), a San Diego-based biotech company. Trutino Biosciences...

Broadly neutralizing antibodies could provide immu…

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published Ju...

Novel drug combo activates natural killer cell imm…

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, the...

Novartis announces Nature Medicine publication of …

Novartis announced that Nature Medicine published final results from both the two- and three-copy cohorts of the completed Phase 3 SPR1NT trial as separate companion manu...

COVID-19 rebound after taking Paxlovid likely due …

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was ...

Biomarkers found that could be drug targets agains…

Biomarkers that could be targets for novel drugs to treat glioblastoma brain tumors have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Cent...